Endocrine therapy remains a backbone of adjuvant therapy for women with hormone receptor–positive early-stage breast cancer. Numerous studies have demonstrated the benefit of ovarian function ...
Stephen Johnston, Ph.D., from the Royal Marsden NHS Foundation Trust in London, and colleagues reported the primary OS results for patients with HR-positive, HER2-negative, node-positive, high-risk ...
Some patients with breast cancer who took Verzenio plus endocrine therapy two years after initial treatment demonstrated improved efficacy. Two years of Verzenio (abemaciclib) plus endocrine therapy ...
Regarding the Addition of CDK4/6 Inhibitor to Postoperative Endocrine Therapy in Patients With HR-Positive HER2-Negative High-Risk Breast Cancer The following represents disclosure information ...
In a video interview, Nancy Lin, MD, of Dana-Farber Cancer Institute, talked about an analysis of HERA trial data presented at ESMO Congress. The study showed the benefit of integrating ovarian ...
Hosted on MSN
Abemaciclib + Endocrine Therapy Improves Survival in HR-Positive, HER2-Negative Early Breast Cancer
THURSDAY, Oct. 23, 2025 (HealthDay News) -- For patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node-positive, high-risk early breast cancer (EBC), ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback